Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Aimmune Therapeutics Inc    AIMT

AIMMUNE THERAPEUTICS INC (AIMT)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/15/2018 10/16/2018 10/17/2018 10/18/2018 10/19/2018 Date
26.63(c) 28.28(c) 28.89(c) 27.71(c) 27.29(c) Last
352 581 601 035 562 048 443 322 291 206 Volume
+0.99% +6.20% +2.16% -4.08% -1.52% Change
More quotes
Financials (USD)
Sales 2018 -
EBIT 2018 -214 M
Net income 2018 -209 M
Finance 2018 178 M
Yield 2018 -
Sales 2019 22,3 M
EBIT 2019 -212 M
Net income 2019 -195 M
Finance 2019 57,8 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 0
EV / Sales2019 70,1x
Capitalization 1 620 M
More Financials
Company
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies.Its portfolio includes the characterized oral desensitization immunotherapy system.The company was founded on... 
Sector
Pharmaceuticals
Calendar
11/06Earnings Release
More about the company
Surperformance© ratings of Aimmune Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on AIMMUNE THERAPEUTICS INC
10/17AIMMUNE THERAPEUTICS : Announces Initiation of Phase 2 Study With Regeneron and ..
AQ
10/16AIMMUNE THERAPEUTICS : Announces Initiation of Phase 2 Study With Regeneron and ..
AQ
10/15AIMMUNE THERAPEUTICS : Announces Initiation of Phase 2 Study With Regeneron and ..
BU
10/11CERUS : Appoints Eric Bjerkholt to Board of Directors
AQ
09/28AIMMUNE THERAPEUTICS : to Present at the Cantor Global Healthcare Conference on ..
AQ
09/26AIMMUNE THERAPEUTICS : to Present at the Cantor Global Healthcare Conference on ..
BU
08/29AIMMUNE THERAPEUTICS : to Present at Three Investor Conferences in September
BU
08/10AIMMUNE THERAPEUTICS : Announces CEO Jayson Dallas Will Present at the Wedbush P..
AQ
08/08AIMMUNE THERAPEUTICS : 2Q Earnings Snapshot
AQ
08/08AIMMUNE THERAPEUTICS : Management's Discussion and Analysis of Financial Conditi..
AQ
More news
Sector news : Specialty & Advanced Pharmaceuticals
10/19FDA Approves Asthma Indication for Regeneron and Sanofi's Dupixent
DJ
10/19ABBVIE : CFO Chase to retire by mid-year 2019
RE
10/19MYLAN : Launches Hulio, a Biosimilar to Humira, in Europe
DJ
10/19FDA Approves Label Update for Genentech's Rituxan
DJ
10/19ABBVIE : Chief Financial Officer Chase to Retire; Michael Takes Post
DJ
More sector news : Specialty & Advanced Pharmaceuticals
Latest Tweets
10/19Get the latest news and updates for $HDNG $USX $PRT $AIMT $YGE automatically .. 
10/18Aimmune Therapeutics $AIMT Stock Rating Upgraded by BidaskClub  
10/17Breakout stocks up the most since yesterday  
10/17BidaskClub Upgrades Aimmune Therapeutics $AIMT to “Hold”  
10/17Aimmune Therapeutics $AIMT Given a $62.00 Price Target by Cantor Fitzgerald A.. 
More tweets
Qtime:41
News from SeekingAlpha
10/15Aimmune teams up with Regeneron and Sanofi in mid-stage peanut allergy study;.. 
09/24AIMMUNE : To Capture The Vast Food Allergy Market 
09/06Intrommune advancing peanut allergy candidate, pre-IND meeting with FDA compl.. 
08/13Here, Take Another Hit Of This, Then Sell Some More Aimmune 
08/13AIMMUNE AND DBV TECHNOLOGIES : A Comparison 
Chart AIMMUNE THERAPEUTICS INC
Duration : Period :
Aimmune Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AIMMUNE THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 56,6 $
Spread / Average Target 104%
EPS Revisions
Managers
NameTitle
Jayson Donald Alexander Dallas President, Chief Executive Officer & Director
Mark D. McDade Chairman
Jeffrey H. Knapp Chief Operating Officer
Eric H. Bjerkholt Chief Financial Officer
Daniel C. Adelman Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
AIMMUNE THERAPEUTICS INC-29.59%1 620
ABBVIE-7.79%136 133
MERCK KGAA-1.53%13 726
KYOWA HAKKO KIRIN CO LTD-7.70%10 597
JAZZ PHARMACEUTICALS PLC15.31%9 424
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD40.90%6 989